Floatz logo

Ranolazine

Diabetic Peripheral Neuropathic Pain

Horizons International Peripheral GroupSmall moleculePhase 4 / ApprovedDormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
81/ 100

Competitive context

28 Active assets in the Diabetic Peripheral Neuropathic Pain cohort.

Asset / SponsorPhaseRating
Duloxetine
Aga Khan University
Phase 4A
Duloxetine
Eli Lilly and Company
Phase 4BBB
ds-5565
Bangladesh Medical University
Phase 4BBB
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)-
Aziende Chimiche Riunite Angelini Francesco S.p.A
Phase 4BBB
Capsaicin
Corporacion Parc Tauli
Phase 4BBB

View all 50 →

Same molecule, other indications

Ranolazine is also rated in:

myocardial ischemiaDormant
A
Indicative ·
82 / 100
View asset →
coronary artery disorderDormant
BBB
Indicative ·
75 / 100
View asset →
myocardial ischemiaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →